Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Repeat retroperitoneal lymph node dissection for metastatic testis cancer.

Wade J Sexton1, Christopher G Wood, Richard Kim

  • 1Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

The Journal of Urology
|March 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hearing preservation and restoration surgery in NF2-related schwannomatosis.

Familial cancer·2026
Same author

Hearing Loss, Brain Structure, Cognition, and Dementia Risk in the Framingham Heart Study.

JAMA network open·2025
Same author

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.

European urology oncology·2025
Same author

Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas.

The Laryngoscope·2025
Same author

Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers.

Cells·2025
Same author

Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre.

Cancers·2025

Repeat retroperitoneal lymph node dissection is safe and effective for metastatic testis cancer patients with recurrent masses. This procedure offers good outcomes, though careful planning is needed due to potential vascular complications.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Urologic Oncology

Background:

  • Metastatic testis cancer often requires multimodal treatment, including retroperitoneal lymph node dissection (RPLND).
  • Recurrence or residual disease after initial treatment may necessitate repeat RPLND.
  • Repeat RPLND presents unique challenges and requires careful evaluation of outcomes.

Purpose of the Study:

  • To report pathological findings, perioperative complications, and patient outcomes.
  • To evaluate the safety and efficacy of repeat retroperitoneal lymph node dissection.
  • To analyze morbidity and mortality associated with repeat RPLND in metastatic testis cancer.

Main Methods:

  • Retrospective review of an institutional tumor registry.
  • Identification of 417 patients undergoing RPLND for testis cancer over 21 years.

Related Experiment Videos

  • Detailed analysis of 21 patients who underwent repeat RPLND, including preoperative, operative, and postoperative data.

    • Main Results:

    • Pathological findings included viable germ cell tumor (24%), teratoma (67%), and fibrosis/necrosis (24%).
    • Significant intraoperative vascular complications occurred in 2 cases, requiring aortic grafting in one.
    • Common postoperative complications included prolonged ileus (29%) and chylous ascites (14%). Six patients died (29%), 5 from disease progression.
    • At a mean follow-up of 4.7 years, 71% of patients were alive and 67% were disease-free.

    Conclusions:

    • Repeat RPLND is a safe and effective procedure for most patients with recurrent or residual metastatic testis cancer.
    • Perioperative morbidity and mortality are generally low.
    • Potential for significant vascular complications necessitates meticulous preoperative planning and intraoperative vigilance.